ES2115096T3 - Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. - Google Patents

Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.

Info

Publication number
ES2115096T3
ES2115096T3 ES94106848T ES94106848T ES2115096T3 ES 2115096 T3 ES2115096 T3 ES 2115096T3 ES 94106848 T ES94106848 T ES 94106848T ES 94106848 T ES94106848 T ES 94106848T ES 2115096 T3 ES2115096 T3 ES 2115096T3
Authority
ES
Spain
Prior art keywords
compounds
tetrazolic
medicines
derivatives
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94106848T
Other languages
English (en)
Inventor
Alfons Dr Enhsen
Heiner Dr Glombik
Werner Dr Dr Kramer
Gunter Dr Wess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2115096T3 publication Critical patent/ES2115096T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE UN DERIVADO TETRAZOL ACIDO BILIAR DE LA FORMULA I DONDE G1, G2 Y X TIENEN EL SIGNIFICADO DADO, ASI COMO PROCESO PARA SU ELABORACION. LOS COMPUESTOS POSEEN PROPIEDADES FARMACOLOGICAS VALIOSAS Y PUEDEN SER UTILIZADOS POR ELLO COMO MEDICAMENTO.
ES94106848T 1993-05-08 1994-05-02 Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. Expired - Lifetime ES2115096T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315368 1993-05-08

Publications (1)

Publication Number Publication Date
ES2115096T3 true ES2115096T3 (es) 1998-06-16

Family

ID=6487579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94106848T Expired - Lifetime ES2115096T3 (es) 1993-05-08 1994-05-02 Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.

Country Status (19)

Country Link
US (1) US5466815A (es)
EP (1) EP0624596B1 (es)
JP (1) JP3476157B2 (es)
KR (1) KR100333149B1 (es)
AT (1) ATE163938T1 (es)
AU (1) AU666440B2 (es)
CA (1) CA2123048C (es)
CY (1) CY2119B1 (es)
CZ (1) CZ289515B6 (es)
DE (1) DE59405410D1 (es)
DK (1) DK0624596T3 (es)
ES (1) ES2115096T3 (es)
FI (1) FI942075L (es)
GR (1) GR3026496T3 (es)
HU (1) HU217439B (es)
IL (1) IL109581A (es)
NO (1) NO304795B1 (es)
NZ (1) NZ260469A (es)
TW (1) TW289757B (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (es) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
MXPA01011070A (es) 1999-04-30 2003-06-30 Arch Dev Corp Derivados de esteroides.
US7086134B2 (en) * 2000-08-07 2006-08-08 Shipley Company, L.L.C. Alignment apparatus and method for aligning stacked devices
CN1498222A (zh) * 2001-02-08 2004-05-19 芝加哥大学 类固醇衍生物
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
DK1392713T3 (da) * 2001-05-03 2008-02-18 Univ Chicago Lever-X-receptoragonister
US6816317B2 (en) * 2002-01-31 2004-11-09 Lightel Technologies Inc. Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same
EP1494533A2 (en) * 2002-04-12 2005-01-12 The University of Chicago Farnesoid x-activated receptor agonists
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
US8829213B2 (en) * 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
EP3400944B1 (en) 2010-11-04 2020-07-15 Albireo AB Ibat inhibitors for the treatment of liver diseases
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
JP6751020B2 (ja) 2014-06-25 2020-09-02 Ｅａファーマ株式会社 固形製剤及びその着色防止又は着色低減方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
HK1245100A1 (zh) * 2015-02-11 2018-08-24 Enanta Pharmaceuticals, Inc. 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3290429A1 (en) * 2015-04-28 2018-03-07 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Cholic acid derivative, and preparation method and medical use thereof
CA3011619C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750944C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
JP7136802B2 (ja) 2017-04-07 2022-09-13 エナンタ ファーマシューティカルズ インコーポレイテッド スルホニルカルバマート胆汁酸誘導体の調製のためのプロセス
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
SG11202012170PA (en) 2018-06-20 2021-01-28 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
KR20210116523A (ko) * 2019-01-14 2021-09-27 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 테트라졸론 치환된 스테로이드 및 이의 용도
EP3921027B1 (en) 2019-02-06 2023-07-19 Albireo AB Benzothiazepine compounds and their use as bile acid modulators
EP3921028B1 (en) 2019-02-06 2022-11-09 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4379384A3 (en) * 2019-03-19 2024-08-28 Siemens Healthcare Diagnostics Inc. Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
PE20230234A1 (es) 2019-12-04 2023-02-07 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TWI865673B (zh) 2019-12-04 2024-12-11 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7748451B2 (ja) 2020-08-03 2025-10-02 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
JP2025519406A (ja) * 2022-06-09 2025-06-26 シャンドン ルイ ファーマシューティカル カンパニー リミテッド １９－ノルｃ３，３－二置換ｃ２１－アザシクロ置換ステロイド及びその使用方法
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
CA3259103A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia (di)azepine compounds and their use as bile acid modulators
EP4629997A1 (en) 2022-12-09 2025-10-15 Albireo AB Asbt inhibitors in the treatment of renal diseases
WO2025119319A1 (zh) * 2023-12-08 2025-06-12 山东绿叶制药有限公司 一种gabaa受体调节剂的晶型及其制备方法和应用
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals

Also Published As

Publication number Publication date
JPH06329695A (ja) 1994-11-29
FI942075A7 (fi) 1994-11-09
AU6194794A (en) 1994-11-10
EP0624596A3 (de) 1995-06-07
NO941677D0 (no) 1994-05-06
GR3026496T3 (en) 1998-07-31
CA2123048A1 (en) 1994-11-09
FI942075L (fi) 1994-11-09
CZ113594A3 (en) 1994-12-15
US5466815A (en) 1995-11-14
EP0624596B1 (de) 1998-03-11
HU9401443D0 (en) 1994-08-29
AU666440B2 (en) 1996-02-08
ATE163938T1 (de) 1998-03-15
HU217439B (hu) 2000-01-28
CA2123048C (en) 2005-11-29
CY2119B1 (en) 2002-04-26
IL109581A0 (en) 1994-08-26
HUT67390A (en) 1995-04-28
TW289757B (es) 1996-11-01
CZ289515B6 (cs) 2002-02-13
IL109581A (en) 1998-03-10
NZ260469A (en) 1995-03-28
NO304795B1 (no) 1999-02-15
JP3476157B2 (ja) 2003-12-10
DK0624596T3 (da) 1998-10-07
DE59405410D1 (de) 1998-04-16
FI942075A0 (fi) 1994-05-05
EP0624596A2 (de) 1994-11-17
NO941677L (no) 1994-11-09
KR100333149B1 (ko) 2002-09-19

Similar Documents

Publication Publication Date Title
ES2115096T3 (es) Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2136677T3 (es) Derivados monomeros de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2122076T3 (es) Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
ES2013067A6 (es) Un procedimiento para producir un derivado de piperazina.
MX9203677A (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
YU56995A (sh) Soli derivata indola
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
ES2093979T3 (es) Esteres nitricos de derivados del acido 2-(2,6-dihalofenilamino)fenilacetico y su procedimiento de preparacion.
ATE235459T1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
ES2082755T3 (es) Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios.
BR9912109A (pt) Compostos, composições farmacêuticas, processo para a manufatura de um composto, e, método de tratar um mamìfero sofrendo de inflamação patológica e autoimunidade
NO932120L (no) Bifenylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
ES8103170A1 (es) Un procedimiento para obtener una sustancia antibiotica
ES8305714A1 (es) Procedimiento para la produccion de derivados de piperidile-no
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
ES2045009T3 (es) El acido taurohyodesoxicolico para la terapia de calculosis del tracto biliar y de la dispepsia biliar.
ES2044901T3 (es) Procedimiento para la preparacion de un derivado de imidazol y su utilizacion.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2054738T3 (es) Derivados de acido 3-desmetil-4-fluoromevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su empleo y productos intermedios.
MX9301723A (es) Derivados de carbinol di-arilo puenteados, composiciones y metodos de uso.
AR248394A1 (es) Procedimiento para obtener nuevos derivados de la n-bencilpiridina.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ES2182086T3 (es) Nuevos derivados de peptidil-arginina aldehido.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624596

Country of ref document: ES